CARAT – Chimeric Antigen Receptors (CARs) for Advanced Therapies

CARAT project goal

We will develop a more efficient and safer technology platform for advanced cellular therapies, namely to manufacture CAR T-cell products for personalized treatment of cancer patients. Recent Success Stories of CAR-based therapies have raised enormous expectations to cure severely ill patients. Initial clinical studies demonstrated considerable evidence that the artificial recognition molecules allow specific targeting of immune responses towards complete and stable eradication of cancer cells. Translation into the clinic of such advanced therapeutic concepts is still extremely difficult as the manufacture of CAR-modified T-cells is technologically complex and expensive. 

For more information visit the CARAT website.

How will we get there? 

The CARAT technology platform will enable the automated, safe, and cost efficient manufacture of more effective CAR-modified T-cells. Thereby, CARAT will spread the clinical use of CAR T-cell technologies with the ultimate goal of serving patients with so far incurable hematologic malignancies and solid tumours like colon, pancreas or lung cancer – everywhere in Europe.


CARAT training

As part of our dissemination activities within CARAT, we are offering for the third time a training course on “GMP-compliant CAR T Cell Manufacturing”. 

Partners in this collaboration

Ospedale San Raffaele, Bundesinstitut für Impfstoffe und Biomedizinische Arzneimittel, Institut National de la Sante et de la Recherche Medicale, University College London, Trakcel Limited, Universitaetsklinikum Freiburg, Eurice European Research And Project Office Gmbh

Funded by the European Union, GA 667980

Seems like you are coming from USA!
Do you want to visit our website in your country?